Treatment options for men with metastatic castration-resistant prostate cancer have increased dramatically over the past few years. Models predicting survival can help clinicians and patients choose the best approach, but it is more than 10 years since the last prognostic model became available. At the recent European Cancer Congress (Amsterdam; 27 Sept-1st October 2013) Susan Halabi (Duke University, Durham, N Carolina, USA) presented data on a new validated prognostic model for overall survival in chemotherapy-naïve patients (#2851). Here, she explains to medical journalist Helen Saul how the new model will enhance individualised care and improve patient selection for clinical trials.
The content of the videos, articles and all statements expressed therein do not necessarily reflect the opinions or views of the Editors, Authors or Reviewers of European Urology.